Biblioteca Hospital 12 de Octubre
Vista normal Vista MARC Vista ISBD

Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer [artículo]

Por: Aldea, M [Instituto de Investigación i+12] | Cuezva, J.M [Instituto de Investigación i+12] | Núñez de Arenas, Cristina [Instituto de Investigación i+12].
Colaborador(es): Instituto de Investigación imas12.
Editor: Cancer Letters, 2011Descripción: 311(2):210-218.Recursos en línea: Solicitar documento Resumen: A reverse phase protein microarray approach has been applied to quantify proteins of energy metabolism in normal and tumor biopsies of colorectal cancer (CRC) patients. The metabolic proteome of CRC specimens revealed a profound shift towards and enhanced glycolytic phenotype and concurrent mitochondrial alteration. The metabolic signature discriminated CRC patients with highly significant differences in overall and disease-free prognosis. The quantification of the bioenergetic signature of the tumor offers a relevant biomarker of CRC that could contribute in the handling of these patients.
Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.
    valoración media: 0.0 (0 votos)
Tipo de ítem Ubicación actual Signatura Estado Fecha de vencimiento
Artículo Artículo PC7672 (Navegar estantería) Disponible

Formato Vancouver:
Aldea M, Clofent J, Núñez de Arenas C, Chamorro M, Velasco M, Berrendero JR, et al. Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer. Cancer Lett. 2011;311(2):210-8.

PMID: 21880415

Contiene 41 referencias

A reverse phase protein microarray approach has been applied to quantify proteins of energy metabolism in normal and tumor biopsies of colorectal cancer (CRC) patients. The metabolic proteome of CRC specimens revealed a profound shift towards and enhanced glycolytic phenotype and concurrent mitochondrial alteration. The metabolic signature discriminated CRC patients with highly significant differences in overall and disease-free prognosis. The quantification of the bioenergetic signature of the tumor offers a relevant biomarker of CRC that could contribute in the handling of these patients.

No hay comentarios para este ejemplar.

Ingresar a su cuenta para colocar un comentario.

Con tecnología Koha